Subsidiary Of Jiuzhoutong Obtains Marketing Authorization Approval Notice For Chemical API L-Malic Acid

Dec 02, 2025

Leave a message

Jiuzhoutong Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company" or "Jiuzhoutong")

Its holding subsidiary, Beijing Jingfeng Pharmaceutical (Shandong) Co., Ltd., received the "Marketing Authorization Approval Notice for Chemical Active Pharmaceutical Ingredient (API)" approved and issued by the National Medical Products Administration (NMPA) on December 20, 2024, for the marketing application of L-Malic Acid. The relevant information is hereby announced as follows:

 

I. Key Information of the Marketing Authorization Approval Notice

 

Chemical API Name: L-Malic Acid (Generic Name); L-Malic Acid (English Name/Latin Name)

Registration Number: Y20210000645

Chemical API Registration Standard Number: YBY76452024

Packaging Specification: 10kg/drum

Application Item: Marketing application for domestically produced chemical API

Manufacturer: Beijing Jingfeng Pharmaceutical (Shandong) Co., Ltd.

Validity Period of the Notice: Until December 19, 2029

Approval Conclusion: In accordance with the "Drug Administration Law of the People's Republic of China" and relevant regulations, after review, this product meets the relevant requirements for drug registration and is approved for registration.

 

II. Other Relevant Information About the Product

 

L-Malic Acid is widely used in drugs for liver dysfunction, uremia, hypertension, cancer, heart disease, and other conditions. Adding L-Malic Acid to drugs can enhance their stability, promote the absorption and diffusion of drugs in the human body, and simultaneously reduce the toxic effects of anti-cancer drugs on normal cells.

L-Malic Acid is the API for Compound Electrolyte Injection (II), which is mainly used for the treatment of acidotic dehydration and supplementation of extracellular fluid. Currently, it is widely recommended by multiple domestic and international authoritative guidelines and has extensive clinical applications. According to Yaozhi Data, the hospital sales of Compound Electrolyte Injection (II) exceeded RMB 150 million in both 2022 and 2023. The main manufacturer is B. Braun (Germany), and there are relatively few domestic manufacturers at present, indicating promising development prospects.

Send Inquiry
Contact usif have any question

You can either contact us via phone, email or online form below. Our specialist will contact you back shortly.

Contact now!